Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 436.75 0 (0%) Market Cap: 114.49 Bil Enterprise Value: 109.92 Bil PE Ratio: 0 PB Ratio: 7.74 GF Score: 72/100

Vertex Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 03:00PM GMT
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good morning, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Vertex with us for the next session.

Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures.

So before we get into Q&A, I'm going to turn it over to Reshma to make some opening comments, and then we'll jump right into it.

Reshma Kewalramani
Vertex Pharmaceuticals Incorporated - CEO, President & Director

Great. Hey, thanks, Matt, for the invitation to participate, and good morning all. I also will be making some statements because there are some risks and uncertainties that could impact the actual events of our business. I'll direct you to our SEC filings where this is all discussed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot